Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 3/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | MC5R | P33032 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449777 | 0.97 | ITGA4 (0.47) | ITGA4MC4RMC5RITGB1ITGB7 | |
| SCHEMBL4455548 | 0.93 | ITGA4 (0.52) | ITGA4MC4RMC5RITGB1ITGB7 | |
| SCHEMBL3849746 | 0.85 | ITGA4 (0.51) | ITGA4ITGB1ITGB7CACNA1BITGA5 | |
| SCHEMBL3850688 | 0.85 | ITGA4 (0.51) | ITGA4ITGB1ITGB7CACNA1BMCL1 | |
| SCHEMBL3851145 | 0.85 | ITGA4 (0.54) | ITGA4ITGB1ITGB7CACNA1BKMT2A | |
| SCHEMBL3849743 | 0.85 | ITGA4 (0.55) | ITGA4ITGB1ITGB7KMT2AITGA5 | |
| SCHEMBL3852367 | 0.83 | ITGA4 (0.50) | ITGA4ITGB1ITGB7CASP3CACNA1B | |
| SCHEMBL3857921 | 0.83 | ITGA4 (0.54) | ITGA4ITGB1ITGB7CACNA1BITGA5 | |
| SCHEMBL3852903 | 0.82 | ITGA4 (0.55) | ITGA4ITGB1ITGB7KMT2AITGA5 | |
| SCHEMBL3848814 | 0.82 | ITGA4 (0.53) | ITGA4ITGB1ITGB7CACNA1BITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2003-01-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ITGA4 8/4885MC4R 1531/4885MC5R 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.